U.S. Markets close in 57 mins
  • S&P 500

    4,371.76
    +14.03 (+0.32%)
     
  • Dow 30

    34,046.09
    +75.62 (+0.22%)
     
  • Nasdaq

    14,809.80
    +95.90 (+0.65%)
     
  • Russell 2000

    2,187.53
    +5.33 (+0.24%)
     
  • Crude Oil

    70.51
    +0.22 (+0.31%)
     
  • Gold

    1,775.80
    +12.00 (+0.68%)
     
  • Silver

    22.53
    +0.37 (+1.68%)
     
  • EUR/USD

    1.1730
    +0.0003 (+0.0235%)
     
  • 10-Yr Bond

    1.3240
    +0.0150 (+1.15%)
     
  • Vix

    23.92
    -1.79 (-6.96%)
     
  • GBP/USD

    1.3668
    +0.0009 (+0.0642%)
     
  • USD/JPY

    109.2150
    -0.2050 (-0.1874%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,049.09
    -14.76 (-1.39%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Abiomed (ABMD) Enters Overbought Territory

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Abiomed, Inc. ABMD has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because ABMD is now in overbought territory with an RSI value of 74.28.

What is RSI?

RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.

Other Factors

Yet ABMD’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions Abiomed’s stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of ABMD’s prospects for the near term.

Over the past one month, investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for ABMD’s has also been on a downward trend over the same time period too, as the estimates have fallen 8.5% over the last two months.

If this wasn’t enough, Abiomed also has a Zacks Rank #5 (Strong Sell)which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research